Abstract P126: Site-1 Protease-Derived Soluble (pro)renin Receptor Targets Renal V2 Vasopressin Receptor/AQP2 to Enhance Urine Concentrating Capability

Fei Wang,Kexin Peng,Chuanming Xu,Shiying Xie,Renfei Luo,Chang-jiang Zou,Tianxin Yang
DOI: https://doi.org/10.1161/hyp.72.suppl_1.p126
IF: 9.8968
2018-01-01
Hypertension
Abstract:Our previous study demonstrates that exogenous soluble (pro)renin receptor (sPRR-His) exerts a biological function in regulation of AQP2 expression and urine concentrating capability. The site-1 protease (S1P) has recently been identified as a predominant protease responsible for generation of sPRR. In the present study, we employed pharmacologic and conditional gene knockout studies to test the potential role of S1P-derived sPRR in regulation of fluid homeostasis. In C57/BL6 mice, treatment with a S1P inhibitor PF429242 (PF at 20 mg/kg/d via minipump for 4 days) induced polyuria (urine volume: PF: 1.6 ± 0.4 vs. Vehicle: 0.7 ± 0.2 ml, p <0.05) accompanied with 50% reduction of urine osmolality and reduced AVP sensitivity (PF: 22.6% ± 4.0% vs. Vehicle: 74.2% ± 5.0%, p <0.01), all of which were nearly completely reversed by sPRR-His treatment via intravenous infusion at 30 μg/kg/d. AVP sensitivity was determined by measurement of urinary osmolality response to acute AVP injection. Immunoblotting demonstrated that PF infusion induced a parallel reduction of protein abundance of V2R (70% off) and AQP2 (80% off). Interestingly, sPRR-His infusion restored the expression of V2R and AQP2. We have developed an inducible renal tubule-wide deletion of site-1 protease using the Pax8/LC1 transgenes (termed as RT S1P KO). RT S1P KO mice exhibited similar polyuria (urine volume: KO: 1.8 ± 0.2 vs. Floxed: 1.1 ± 0.2 ml/day, p<0.01) associated with suppressed renal expression of AQP2 and V2R, as well as impaired AVP sensitivity (KO: 64.5% ± 6.0% vs. Vehicle: 150.2% ± 21.0%, p<0.01). Administration of sPRR-His to RT S1P KO mice reversed polyuria (urine volume: KO+sPRR-His: 1.0 ± 0.2 vs. KO: 1.8 ± 0.2 ml/day, p<0.01) accompanied with restored renal expression of AQP2 and V2R, and AVP sensitivity. These results suggested that S1P acts via its PRR cleaving property to control the activity of AVP/V2R/AQP pathway and thus urine concentrating capability.
What problem does this paper attempt to address?